<DOC>
	<DOCNO>NCT02312440</DOCNO>
	<brief_summary>Recently , interest apply tranexamic acid topically closure surgical wound total hip replacement . It advantage ease application , maximum concentration site bleeding , minimise systematic absorption , potentially , decline risk systematic side-effects 。</brief_summary>
	<brief_title>Comparison Topical Intravenous Tranexamic Acid Total Hip Arthroplasty</brief_title>
	<detailed_description>Objectives : To assess efficacy safety two different apply route . Patients project randomly divide three group , one group blank group rest two group receive either topical intravenous form tranexamic acid unilateral THA ( total hip arthroplasty ) .The total blood loss ( TBL ) calculate primary outcome efficacy event Deep Vein Thrombosis、Pulmonary Embolism、Acute Myocardial Infarction 、 Acute Kidney Infarction Cerebral Infarction record assess safety tranexamic acid six-week follow-up patient . All surgery general anesthesia , direct lateral approach cementless prosthesis . For patient , drain tube clamp close completely 2 hour ; clamp fully open .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>1 . Consented join project . 2 . Adult patient ( great 18 year old ) 3 . Patients schedule primary unilateral hip arthroplasty Patients Ruijin hospital , Shanghai , China 1 . Patients refuse sign Inform Consent 2 . Had allergy TXA . 3. longterm bed &gt; =3 week . 4 . Using anticoagulant drug within week . 5 . Coagulopathy ( preoperative platelet count &lt; 150,000/mm3 , INR &gt; 1.4 , prolong Activated Partial Thromboplastin Time，Prothrombin Time ，or thrombin time ( &gt; 1.4 time longer normal ) 6 . Pregnancy 7 . Breastfeeding 8 . Major comorbidities : Severe ischemic heart disease ( class III IV New York Heart Association ) ; sleep apnea syndrome ; renal dysfunction ( glomerular filtration rate &lt; 60 ) ; hepatic disfunction ( glutamicpyruvic transaminase &gt; 80 glutamic oxalacetic transaminase &gt; 80 ) .Retinopathy ( disturbance color vision ) . 9 . History thromboembolic disease : . 10 . Been participate participate within year another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>tranexamic acid</keyword>
	<keyword>blood loss</keyword>
	<keyword>topical administration</keyword>
	<keyword>intravenous administration</keyword>
</DOC>